Abstract
Over the last several decades the idea that adenosine (Ado) plays a role in sleep control was postulated due in large part to pharmacological studies that showed the ability of Ado agonists to induce sleep and Ado antagonists to decrease sleep. A second wave of research involving in vitro cellular analytic approaches and subsequently, the use of neurochemical tools such as microdialysis, identified a population of cells within the brainstem and basal forebrain arousal centers, with activity that is both tightly coupled to thalamocortical activation and under tonic inhibitory control by Ado. Most recently, genetic tools have been used to show that Ado receptors regulate a key aspect of sleep, the slow wave activity expressed during slow wave sleep. This review will briefly introduce some of the phenomenology of sleep and then summarize the effect of Ado levels on sleep, the effect of sleep on Ado levels, and recent experiments using mutant mouse models to characterize the role for Ado in sleep control and end with a discussion of which Ado receptors are involved in such control. When taken together, these various experiments suggest that while Ado does play a role in sleep control, it is a specific role with specific functional implications and it is one of many neurotransmitters and neuromodulators affecting the complex behavior of sleep. Finally, since the majority of adenosine-related experiments in the sleep field have focused on SWS, this review will focus largely on SWS; however, the role of adenosine in REM sleep behavior will be addressed.
Current Neuropharmacology
Title: Adenosine and Sleep
Volume: 7 Issue: 3
Author(s): Theresa E. Bjorness and Robert W. Greene
Affiliation:
Abstract: Over the last several decades the idea that adenosine (Ado) plays a role in sleep control was postulated due in large part to pharmacological studies that showed the ability of Ado agonists to induce sleep and Ado antagonists to decrease sleep. A second wave of research involving in vitro cellular analytic approaches and subsequently, the use of neurochemical tools such as microdialysis, identified a population of cells within the brainstem and basal forebrain arousal centers, with activity that is both tightly coupled to thalamocortical activation and under tonic inhibitory control by Ado. Most recently, genetic tools have been used to show that Ado receptors regulate a key aspect of sleep, the slow wave activity expressed during slow wave sleep. This review will briefly introduce some of the phenomenology of sleep and then summarize the effect of Ado levels on sleep, the effect of sleep on Ado levels, and recent experiments using mutant mouse models to characterize the role for Ado in sleep control and end with a discussion of which Ado receptors are involved in such control. When taken together, these various experiments suggest that while Ado does play a role in sleep control, it is a specific role with specific functional implications and it is one of many neurotransmitters and neuromodulators affecting the complex behavior of sleep. Finally, since the majority of adenosine-related experiments in the sleep field have focused on SWS, this review will focus largely on SWS; however, the role of adenosine in REM sleep behavior will be addressed.
Export Options
About this article
Cite this article as:
Bjorness E. Theresa and Greene W. Robert, Adenosine and Sleep, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152182
DOI https://dx.doi.org/10.2174/157015909789152182 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Life Under Stress: The Probiotic Stress Response and How it may be Manipulated
Current Pharmaceutical Design Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design Interleukin-1 Drives Cerebrovascular Inflammation via MAP Kinase-Independent Pathways
Current Neurovascular Research The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap
Current Pharmaceutical Design An Improved and Simple Route for the Synthesis of 3-Quinuclidinone Hydrochloride
Letters in Organic Chemistry Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Emerging Role of TRP Channels in Mechanisms of Temperature and Pain Sensation
Current Neuropharmacology Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology NAP, A Neuroprotective Drug Candidate in Clinical Trials, Stimulates Microtubule Assembly in the Living Cell
Current Alzheimer Research Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets Plant Extracts as a Natural Source of Bioactive Compounds and Potential Remedy for the Treatment of Certain Skin Diseases
Current Pharmaceutical Design Psychoactive Plants Described in a Brazilian Literary Work and their Chemical Compounds
Central Nervous System Agents in Medicinal Chemistry Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer
Current Drug Delivery The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued) Disaster Psychiatry: Good Intentions Seeking Science and Sustainability
Adolescent Psychiatry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Molecular Hydrogen as a Neuroprotective Agent
Current Neuropharmacology Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design Biomarkers of Cell Damage Induced by Oxidative Stress in Parkinsons Disease and Related Models
Central Nervous System Agents in Medicinal Chemistry